Trial Profile

Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE"

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary)
Indications Bone cancer; Giant cell tumours
Focus Adverse reactions; Therapeutic Use
Acronyms REDUCE

Most Recent Events

15 Jan 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
04 Jan 2021 Status changed from recruiting to discontinued.
06 Nov 2020 This trial has been completed in Denmark and France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com